What was the effectiveness percentage for both the live varicella and recombinant zoster vaccines after two doses?

The effectiveness of both the live varicella vaccine and the recombinant zoster vaccine is indeed over 90% after two doses. This high level of effectiveness is notable and is a significant reason why these vaccines are routinely recommended for individuals to provide protection against varicella (chickenpox) and herpes zoster (shingles).

The live varicella vaccine has demonstrated robust efficacy in preventing chickenpox among vaccinated populations. The recombinant zoster vaccine has also shown a similar trend, providing strong immunity against the reactivation of the varicella-zoster virus that leads to shingles.

In clinical studies, the results have consistently indicated effectiveness ratings that surpass the 90% mark for both vaccines. Such high efficacy has contributed to substantial public health benefits by reducing the incidence of these diseases in vaccinated individuals. Additionally, it underscores the importance of completing the vaccination schedule to maximize protection.